title: Celecoxib improves the efficiency of the locomotor mechanism in patients with knee osteoarthritis. A randomised, placebo, double-blind and cross-over trial.
abstract: OBJECTIVE
  To compare the effect of celecoxib vs placebo treatment on clinical and gait variables in knee osteoarthritis (OA) patients; focusing on the efficiency of the locomotor mechanism.
  
  
  METHODS
  
  
  
  METHODS
  A prospective, randomised, double-blind placebo-controlled trial.
  
  
  METHODS
  Eight adult patients with painful OA of the knee.
  
  
  METHODS
  Clinical assessment included knee pain assessed by the visual analogue scale, range of knee motion assessed by goniometer, and locomotor function status assessed by a Knee Score Scale. Gait was assessed by means of instrumented analysis including synchronous kinematic, dynamic, electromyographic, and energetic recordings.
  
  
  METHODS
  The effect of treatment on the primary variable, the efficiency of the locomotor mechanism, and on secondary clinical and gait variables was assessed by the Hills and Armitage non-parametric approach.
  
  
  RESULTS
  Celecoxib treatment improved the efficiency of the locomotor mechanism significantly. Among the secondary outcome measures assessed, celecoxib treatment improved walking cadence and reduced the knee pain significantly.
  
  
  CONCLUSIONS
  This study shows that celecoxib is effective in improving locomotor function and pain in patients with knee OA.
authors.affiliation: Rehabilitation and Physical Medicine Unit, Université catholique de Louvain, Brussels, Belgium. detrembleur@read.ucl.ac.be
authors.forename: C
authors.initials: C
authors.lastname: Detrembleur
authors.forename: J
authors.initials: J
authors.lastname: De Nayer
authors.forename: A
authors.initials: A
authors.lastname: van den Hecke
mesh_terms: D000368:Aged; D000886:Anthropometry; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000068579:Celecoxib; D018592:Cross-Over Studies; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D005684:Gait / Q000187:drug effects; D006801:Humans; D007719:Knee Joint / Q000503:physiopathology; D008124:Locomotion / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D020370:Osteoarthritis, Knee / Q000188:drug therapy* / Q000503:physiopathology; D010147:Pain Measurement; D011446:Prospective Studies; D011720:Pyrazoles / Q000627:therapeutic use*; D016059:Range of Motion, Articular; D013449:Sulfonamides / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib